We are live on ! Find out more
BCYC

Bicycle Therapeutics

110 hedge funds and large institutions have $286M invested in Bicycle Therapeutics in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 37 increasing their positions, 21 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

223% more call options, than puts

Call options by funds: $407K | Put options by funds: $126K

107% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 14

76% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 21

16% more funds holding

Funds holding: 95110 (+15)

1.21% less ownership

Funds ownership: 87.48%86.26% (-1.2%)

19% less capital invested

Capital invested by funds: $354M → $286M (-$68M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
110
Holders Change
+15
Holders Change %
+15.79%
% of All Funds
1.45%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
29
Increased
37
Reduced
21
Closed
14
Calls
$407K
Puts
$126K
Net Calls
+$281K
Net Calls Change
+$466K
Name Holding Trade Value Shares
Change
Change in
Stake
EP
26
Eversept Partners
New York
$1.47M +$1.68M +211,469 New
Handelsbanken Fonder
27
Handelsbanken Fonder
Sweden
$1.39M -$127K -15,900 -7%
TD Asset Management
28
TD Asset Management
Ontario, Canada
$1.34M
Legal & General Group
29
Legal & General Group
United Kingdom
$1.21M +$313K +39,252 +29%
PA
30
Pinnacle Associates
New York
$1.2M -$337K -42,325 -20%
UOC
31
UBS O'Connor
Illinois
$999K -$39.2K -4,922 -3%
Manulife (Manufacturers Life Insurance)
32
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$976K +$17.9K +2,243 +2%
Citadel Advisors
33
Citadel Advisors
Florida
$969K +$74.8K +9,397 +7%
HCA
34
Harbor Capital Advisors
Illinois
$964K -$75.4K -9,468 -6%
Janney Montgomery Scott
35
Janney Montgomery Scott
Pennsylvania
$697K +$799K +100,291 New
SCM
36
Soleus Capital Management
Connecticut
$695K +$797K +100,000 New
CSS
37
Cubist Systematic Strategies
Connecticut
$610K +$322K +40,468 +86%
MCM
38
Monimus Capital Management
New Jersey
$592K +$679K +85,224 New
MCM
39
Moore Capital Management
New York
$521K +$199K +25,000 +50%
RC
40
Rangeley Capital
Connecticut
$521K +$597K +75,000 New
Two Sigma Advisers
41
Two Sigma Advisers
New York
$488K +$559K +70,200 New
NFGH
42
Nan Fung Group Holdings
Hong Kong
$479K
State Street
43
State Street
Massachusetts
$459K -$157K -19,656 -23%
DCM
44
DAFNA Capital Management
California
$448K -$130K -16,307 -20%
Two Sigma Investments
45
Two Sigma Investments
New York
$391K +$448K +56,198 New
Goldman Sachs
46
Goldman Sachs
New York
$363K +$216K +27,073 +107%
DTL
47
Dynamic Technology Lab
Singapore
$320K +$366K +45,950 New
Skandinaviska Enskilda Banken (SEB)
48
Skandinaviska Enskilda Banken (SEB)
Sweden
$297K
Geode Capital Management
49
Geode Capital Management
Massachusetts
$281K +$152K +19,035 +89%
PP
50
Paloma Partners
Connecticut
$273K +$313K +39,250 New

BCYC Hedge Fund Activity: Q2 2025 in Review

110 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Bicycle Therapeutics (BCYC) for Q2 2025, worth a combined $286M — down 19% from $354M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new BCYC positions and 14 closed out — a net gain of 15 holders — while 37 added to existing stakes and 21 trimmed.

The largest buyer was Millennium Management, adding an estimated $7.89M. The largest seller was Point72 Asset Management, cutting an estimated $15.3M.

  • 110 institutional investors held Bicycle Therapeutics (BCYC) as of Q2 2025, up from 95 in Q1 2025.
  • Funds reported $286M of Bicycle Therapeutics stock for Q2 2025, down 19% quarter-over-quarter.
  • 29 funds opened new Bicycle Therapeutics positions in Q2 2025 and 14 closed out, a net change of +15 holders.
  • The largest Bicycle Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $7.89M added.
  • The largest Bicycle Therapeutics seller in Q2 2025 was Point72 Asset Management, an estimated $15.3M sold.

Based on aggregated 13F filings for Q2 2025.